결핵균 치료 시장 : 제품 유형별, 최종사용자별, 지역별 - 세계 산업 분석, 규모, 점유율, 성장, 동향, 예측(2024-2032년)

The Mycobacterium Tuberculosis Treatment Market report by Persistence Market Research provides an in-depth analysis of the market trends, growth drivers, challenges, and prospective innovations spanning from 2024 to 2032. It offers insights into the current landscape and future projections of the market.

The global market for Mycobacterium tuberculosis treatment is expected to achieve a compound annual growth rate (CAGR) of 1.2% from USD 2.13 billion in 2024 to USD 2.40 billion by 2032.

Key Insights:

• Estimated Market Size (2024): USD 2.13 Billion
• Projected Market Size (2032): USD 2.40 Billion
• Global Market Growth Rate (CAGR 2024 to 2032): 1.2%

Mycobacterium Tuberculosis Treatment Market - Report Scope:

Mycobacterium tuberculosis is the bacterium that causes tuberculosis (TB), primarily affecting the lungs but can invade other organs. This report focuses on the drivers promoting the demand for TB treatment, including the global rise in TB cases, increased funding for TB research, and enhancements in diagnostic technologies.

Market Growth Drivers:

The demand for TB treatment is escalating due to several factors. The increase in TB cases globally, enhanced screening and diagnostic measures, and the development of faster-acting and more effective drug regimens drive this growth. The rise of drug-resistant TB forms has spurred research into novel treatment approaches, including combination therapies and longer-term vaccine strategies. Additionally, global health initiatives and funding for TB programs significantly propel market expansion.

Market Restraints:

The Mycobacterium Tuberculosis Treatment Market faces challenges such as the high cost of advanced TB drugs, limited access to medical facilities in low-income countries, and significant rates of treatment non-compliance. The complexity of managing drug-resistant TB and the long duration of treatment also hinder market growth. Regulatory complexities and varying government policies across countries can delay the introduction of new treatments.

Market Opportunities:

Significant opportunities exist for innovation within the TB treatment market. Advances in molecular biology and genetic engineering offer potential for developing new treatments that are more effective against drug-resistant strains of TB. Public-private partnerships and international collaborations can accelerate research and development efforts, while increasing public health campaigns can raise awareness and improve early detection and compliance with treatment protocols.

Key Questions Addressed in the Report:

• What is the Expected CAGR of the Mycobacterium Tuberculosis Treatment Market from 2024 to 2032?
• What are the Key Factors Driving the Growth of the Mycobacterium Tuberculosis Treatment Market?
• Which Treatment Modality Holds the Largest Market Share?
• Who are the Key Players in the Global Mycobacterium Tuberculosis Treatment Market?
• What Strategies are Adopted by Leading Companies to Remain Competitive?

Competitive Landscape and Business Strategies:

Key players in the market include Johnson & Johnson, Sanofi, Bayer AG, and GlaxoSmithKline plc. These companies focus on innovations in TB treatment, market penetration in untapped regions, and forming strategic partnerships to stay competitive. For instance, Johnson & Johnson offers Sirturo for multi-drug resistant TB, and Sanofi has been involved in developing booster combinations to enhance treatment efficacy.

Key Companies Profiled:

• AstraZeneca
• Johnson & Johnson Private Limited
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd.
• Mylan N.V.
• Teva Pharmaceutical Industries Ltd.
• Sanofi
• Novartis AG
• Sun Pharmaceutical Industries Ltd.
• Aurobindo Pharma
• Lupin
• Allergan
• Merck & Co., Inc.
• Pfizer Inc.
• GlaxoSmithKline plc
• Hikma Pharmaceuticals PLC
• Cipla Inc.
• Endo International plc
• Otsuka Pharmaceutical Co., Ltd.
• STI Pharma, LLC

Mycobacterium Tuberculosis Treatment Market Segmentation:

By Disease Type:

• Latent TB
• Active TB

By Treatment Type:

• First-Line of Drugs
• Second-Line of Drugs

By Route of Administration:

• Oral
• Intravenous
• Intramuscular

By Distribution Channel:

• Hospital Pharmacies
• Online Pharmacies
• Retail Pharmacies
• Institutional and Retail Sales

By Region:

• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• Middle East & Africa

Table of Contents

1. Executive Summary

• 1.1. Global Market Outlook
• 1.2. Demand Side Trends
• 1.3. Supply-Side Trends
• 1.4. Analysis and Recommendations

2. Market Overview

• 2.1. Market Coverage / Taxonomy
• 2.2. Market Definition / Scope / Limitations
• 2.3. Inclusions & Exclusions

3. Key Market Trends

• 3.1. Key Trends Impacting the Market
• 3.2. Product Innovation / Development Trends

4. Key Success Factors

• 4.1. Disease Epidemiology, By Region
• 4.2. Regulatory Scenario
• 4.3. PESTLE Analysis
• 4.4. Porter's Analysis
• 4.5. Key Promotional Strategies, by Manufacturers
• 4.6. Supply Chain Analysis

5. Market Background

• 5.1. Macro-Economic Factors
  • 5.1.1. Global GDP Growth Outlook
  • 5.1.2. Global Healthcare Expenditure
  • 5.1.3. Global Infectious Disease Treatment Market
• 5.2. Forecast Factors - Relevance & Impact
  • 5.2.1. Growing Burden of Tuberculosis Disease
  • 5.2.2. Increasing Research and Development Activities
  • 5.2.3. Adoption of Different Treatments for Infectious Disease
  • 5.2.4. Rising Government Support
  • 5.2.5. Increasing FDA Approvals of New Drugs
  • 5.2.6. Strategic Mergers and Acquisitions Among Local Manufacturers
• 5.3. Market Dynamics
  • 5.3.1. Drivers
  • 5.3.2. Restraints
  • 5.3.3. Opportunity Analysis

6. COVID-19 Crisis Analysis

• 6.1. COVID-19 and Impact Analysis
  • 6.1.1. Revenue By Disease Type
  • 6.1.2. Revenue By Treatment Type
  • 6.1.3. Revenue By Route of Administration
  • 6.1.4. Revenue By Distribution Channel
  • 6.1.5. Revenue By Country
• 6.2. 2024 Market Scenario

7. Global Mycobacterium Tuberculosis Treatment Market Demand (in Value or Size in US$ Mn) Analysis 2019-2023 and Forecast, 2024-2032

• 7.1. Historical Market Value (US$ Mn) Analysis, 2019-2023
• 7.2. Current and Future Market Value (US$ Mn) Projections, 2024-2032
  • 7.2.1. Y-o-Y Growth Trend Analysis
  • 7.2.2. Absolute $ Opportunity Analysis

8. Global Mycobacterium Tuberculosis Treatment Market Analysis 2019-2023 and Forecast 2024-2032, By Disease Type

• 8.1. Introduction / Key Findings
• 8.2. Historical Market Size (US$ Mn) Analysis By Disease Type, 2019-2023
• 8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Disease Type, 2024-2032
  • 8.3.1. Latent TB
  • 8.3.2. Active TB
• 8.4. Market Attractiveness Analysis By Disease Type

9. Global Mycobacterium Tuberculosis Treatment Market Analysis 2019-2023 and Forecast 2024-2032, By Treatment Type

• 9.1. Introduction / Key Findings
• 9.2. Historical Market Size (US$ Mn) Analysis By Treatment Type, 2019-2023
• 9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Treatment Type, 2024-2032
  • 9.3.1. First-Line of Drugs
  • 9.3.2. Second-Line of Drugs
• 9.4. Market Attractiveness Analysis By Treatment Type

10. Global Mycobacterium Tuberculosis Treatment Market Analysis 2019-2023 and Forecast 2024-2032, By Route of Administration

• 10.1. Introduction / Key Findings
• 10.2. Historical Market Size (US$ Mn) Analysis By Route of Administration, 2019-2023
• 10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Route of Administration, 2024-2032
  • 10.3.1. Oral
  • 10.3.2. Intravenous
  • 10.3.3. Intramuscular
• 10.4. Market Attractiveness Analysis By Route of Administration

11. Global Mycobacterium Tuberculosis Treatment Market Analysis 2019-2023 and Forecast 2024-2032, By Distribution Channel

• 11.1. Introduction / Key Findings
• 11.2. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2019-2023
• 11.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Distribution Channel, 2024-2032
  • 11.3.1. Hospital Pharmacies
  • 11.3.2. Online Pharmacies
  • 11.3.3. Retail Pharmacies
  • 11.3.4. Institutional and Retail Sales
• 11.4. Market Attractiveness Analysis By Distribution Channel

12. Global Mycobacterium Tuberculosis Treatment Market Analysis 2019-2023 and Forecast 2024-2032, by Region

• 12.1. Introduction
• 12.2. Historical Market Size (US$ Mn) Analysis, By Region, 2019-2023
• 12.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Region, 2024-2032
  • 12.3.1. North America
  • 12.3.2. Latin America
  • 12.3.3. Europe
  • 12.3.4. East Asia
  • 12.3.5. South Asia
  • 12.3.6. Oceania
  • 12.3.7. Middle East and Africa (MEA)
• 12.4. Market Attractiveness Analysis By Region

13. North America Mycobacterium Tuberculosis Treatment Market Analysis 2019-2023 and Forecast 2024-2032

• 13.1. Introduction
• 13.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
• 13.3. Current and Future Market Size (US$ Mn) Analysis and Forecast, By Market Taxonomy, 2024-2032
  • 13.3.1. By Country
    • 13.3.1.1. U.S.
    • 13.3.1.2. Canada
  • 13.3.2. By Disease Type
  • 13.3.3. By Treatment Type
  • 13.3.4. By Route of Administration
  • 13.3.5. By Distribution Channel
• 13.4. Market Attractiveness Analysis
  • 13.4.1. By Country
  • 13.4.2. By Disease Type
  • 13.4.3. By Treatment Type
  • 13.4.4. By Route of Administration
  • 13.4.5. By Distribution Channel
• 13.5. Market Trends
• 13.6. Key Market Participants - Intensity Mapping
• 13.7. Drivers and Restraints - Impact Analysis
• 13.8. Country Level Analysis & Forecast
  • 13.8.1. U.S. Mycobacterium Tuberculosis Treatment Market Analysis
    • 13.8.1.1. Introduction
    • 13.8.1.2. Market Analysis and Forecast by Market Taxonomy
      • 13.8.1.2.1. By Disease Type
      • 13.8.1.2.2. By Treatment Type
      • 13.8.1.2.3. By Route of Administration
      • 13.8.1.2.4. By Distribution Channel
  • 13.8.2. Canada Mycobacterium Tuberculosis Treatment Market Analysis
    • 13.8.2.1. Introduction
    • 13.8.2.2. Market Analysis and Forecast by Market Taxonomy
      • 13.8.2.2.1. By Disease Type
      • 13.8.2.2.2. By Treatment Type
      • 13.8.2.2.3. By Route of Administration
      • 13.8.2.2.4. By Distribution Channel

14. Latin America Mycobacterium Tuberculosis Treatment Market Analysis 2019-2023 and Forecast 2024-2032

• 14.1. Introduction
• 14.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
• 14.3. Current and Future Market Size (US$ Mn) Analysis and Forecast, By Market Taxonomy, 2024-2032
  • 14.3.1. By Country
    • 14.3.1.1. Brazil
    • 14.3.1.2. Mexico
    • 14.3.1.3. Rest of Latin America
  • 14.3.2. By Disease Type
  • 14.3.3. By Treatment Type
  • 14.3.4. By Route of Administration
  • 14.3.5. By Distribution Channel
• 14.4. Market Attractiveness Analysis
  • 14.4.1. By Country
  • 14.4.2. By Disease Type
  • 14.4.3. By Treatment Type
  • 14.4.4. By Route of Administration
  • 14.4.5. By Distribution Channel
• 14.5. Market Trends
• 14.6. Key Market Participants - Intensity Mapping
• 14.7. Drivers and Restraints - Impact Analysis
• 14.8. Country Level Analysis & Forecast
  • 14.8.1. Brazil Mycobacterium Tuberculosis Treatment Market Analysis
    • 14.8.1.1. Introduction
    • 14.8.1.2. Market Analysis and Forecast by Market Taxonomy
      • 14.8.1.2.1. By Disease Type
      • 14.8.1.2.2. By Treatment Type
      • 14.8.1.2.3. By Route of Administration
      • 14.8.1.2.4. By Distribution Channel
  • 14.8.2. Argentina Mycobacterium Tuberculosis Treatment Market Analysis
    • 14.8.2.1. Introduction
    • 14.8.2.2. Market Analysis and Forecast by Market Taxonomy
      • 14.8.2.2.1. By Disease Type
      • 14.8.2.2.2. By Treatment Type
      • 14.8.2.2.3. By Route of Administration
      • 14.8.2.2.4. Distribution Channel
  • 14.8.3. Mexico Mycobacterium Tuberculosis Treatment Market Analysis
    • 14.8.3.1. Introduction
    • 14.8.3.2. Market Analysis and Forecast by Market Taxonomy
      • 14.8.3.2.1. By Disease Type
      • 14.8.3.2.2. By Treatment Type
      • 14.8.3.2.3. By Route of Administration
      • 14.8.3.2.4. By Distribution Channel

15. Europe Mycobacterium Tuberculosis Treatment Market Analysis 2019-2023 and Forecast 2024-2032

• 15.1. Introduction
• 15.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
• 15.3. Current and Future Market Size (US$ Mn) Analysis and Forecast, By Market Taxonomy, 2024-2032
  • 15.3.1. By Country
    • 15.3.1.1. Germany
    • 15.3.1.2. Italy
    • 15.3.1.3. France
    • 15.3.1.4. U.K.
    • 15.3.1.5. Spain
    • 15.3.1.6. BENELUX
    • 15.3.1.7. Nordic Countries
    • 15.3.1.8. Russia
    • 15.3.1.9. Rest of Europe
  • 15.3.2. By Disease Type
  • 15.3.3. By Treatment Type
  • 15.3.4. By Route of Administration
  • 15.3.5. By Distribution Channel
• 15.4. Market Attractiveness Analysis
  • 15.4.1. By Country
  • 15.4.2. By Disease Type
  • 15.4.3. By Treatment Type
  • 15.4.4. By Route of Administration
  • 15.4.5. By Distribution Channel
• 15.5. Market Trends
• 15.6. Key Market Participants - Intensity Mapping
• 15.7. Drivers and Restraints - Impact Analysis
• 15.8. Country Level Analysis & Forecast
  • 15.8.1. Germany Mycobacterium Tuberculosis Treatment Market Analysis
    • 15.8.1.1. Introduction
    • 15.8.1.2. Market Analysis and Forecast by Market Taxonomy
      • 15.8.1.2.1. By Disease Type
      • 15.8.1.2.2. By Treatment Type
      • 15.8.1.2.3. By Route of Administration
      • 15.8.1.2.4. By Distribution Channel
  • 15.8.2. France Mycobacterium Tuberculosis Treatment Market Analysis
    • 15.8.2.1. Introduction
    • 15.8.2.2. Market Analysis and Forecast by Market Taxonomy
      • 15.8.2.2.1. By Disease Type
      • 15.8.2.2.2. By Treatment Type
      • 15.8.2.2.3. By Route of Administration
      • 15.8.2.2.4. By Distribution Channel
  • 15.8.3. Italy Mycobacterium Tuberculosis Treatment Market Analysis
    • 15.8.3.1. Introduction
    • 15.8.3.2. Market Analysis and Forecast by Market Taxonomy
      • 15.8.3.2.1. By Disease Type
      • 15.8.3.2.2. By Treatment Type
      • 15.8.3.2.3. By Route of Administration
      • 15.8.3.2.4. By Distribution Channel
  • 15.8.4. Spain Mycobacterium Tuberculosis Treatment Market Analysis
    • 15.8.4.1. Introduction
    • 15.8.4.2. Market Analysis and Forecast by Market Taxonomy
      • 15.8.4.2.1. By Disease Type
      • 15.8.4.2.2. By Treatment Type
      • 15.8.4.2.3. By Route of Administration
      • 15.8.4.2.4. By Distribution Channel
  • 15.8.5. U.K. Mycobacterium Tuberculosis Treatment Market Analysis
    • 15.8.5.1. Introduction
    • 15.8.5.2. Market Analysis and Forecast by Market Taxonomy
      • 15.8.5.2.1. By Disease Type
      • 15.8.5.2.2. By Treatment Type
      • 15.8.5.2.3. By Route of Administration
      • 15.8.5.2.4. By Distribution Channel
  • 15.8.6. Benelux Union Mycobacterium Tuberculosis Treatment Market Analysis
    • 15.8.6.1. Introduction
    • 15.8.6.2. Market Analysis and Forecast by Market Taxonomy
      • 15.8.6.2.1. By Disease Type
      • 15.8.6.2.2. By Treatment Type
      • 15.8.6.2.3. By Route of Administration
      • 15.8.6.2.4. By Distribution Channel
  • 15.8.7. Nordic Countries Mycobacterium Tuberculosis Treatment Market Analysis
    • 15.8.7.1. Introduction
    • 15.8.7.2. Market Analysis and Forecast by Market Taxonomy
      • 15.8.7.2.1. By Disease Type
      • 15.8.7.2.2. By Treatment Type
      • 15.8.7.2.3. By Route of Administration
      • 15.8.7.2.4. By Distribution Channel
  • 15.8.8. Russia Mycobacterium Tuberculosis Treatment Market Analysis
    • 15.8.8.1. Introduction
    • 15.8.8.2. Market Analysis and Forecast by Market Taxonomy
      • 15.8.8.2.1. By Disease Type
      • 15.8.8.2.2. By Treatment Type
      • 15.8.8.2.3. By Route of Administration
      • 15.8.8.2.4. By Distribution Channel

16. South Asia Mycobacterium Tuberculosis Treatment Market Analysis 2019-2023 and Forecast 2024-2032

• 16.1. Introduction
• 16.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
• 16.3. Current and Future Market Size (US$ Mn) Analysis and Forecast, By Market Taxonomy, 2024-2032
  • 16.3.1. By Country
    • 16.3.1.1. India
    • 16.3.1.2. Thailand
    • 16.3.1.3. Indonesia
    • 16.3.1.4. Malaysia
    • 16.3.1.5. Rest of South Asia
  • 16.3.2. By Disease Type
  • 16.3.3. By Treatment Type
  • 16.3.4. By Route of Administration
  • 16.3.5. By Distribution Channel
• 16.4. Market Attractiveness Analysis
  • 16.4.1. By Country
  • 16.4.2. By Disease Type
  • 16.4.3. By Treatment Type
  • 16.4.4. By Route of Administration
  • 16.4.5. By Distribution Channel
• 16.5. Market Trends
• 16.6. Key Market Participants - Intensity Mapping
• 16.7. Drivers and Restraints - Impact Analysis
• 16.8. Country Level Analysis & Forecast
  • 16.8.1. India Mycobacterium Tuberculosis Treatment Market Analysis
    • 16.8.1.1. Introduction
    • 16.8.1.2. Market Analysis and Forecast by Market Taxonomy
      • 16.8.1.2.1. By Disease Type
      • 16.8.1.2.2. By Treatment Type
      • 16.8.1.2.3. By Route of Administration
      • 16.8.1.2.4. By Distribution Channel
  • 16.8.2. Indonesia Mycobacterium Tuberculosis Treatment Market Analysis
    • 16.8.2.1. Introduction
    • 16.8.2.2. Market Analysis and Forecast by Market Taxonomy
      • 16.8.2.2.1. By Disease Type
      • 16.8.2.2.2. By Treatment Type
      • 16.8.2.2.3. By Route of Administration
      • 16.8.2.2.4. By Distribution Channel
  • 16.8.3. Malaysia Mycobacterium Tuberculosis Treatment Market Analysis
    • 16.8.3.1. Introduction
    • 16.8.3.2. Market Analysis and Forecast by Market Taxonomy
      • 16.8.3.2.1. By Disease Type
      • 16.8.3.2.2. By Treatment Type
      • 16.8.3.2.3. By Route of Administration
      • 16.8.3.2.4. By Distribution Channel
      • 16.8.3.2.5. By Distribution Channel
  • 16.8.4. Thailand Mycobacterium Tuberculosis Treatment Market Analysis
    • 16.8.4.1. Introduction
    • 16.8.4.2. Market Analysis and Forecast by Market Taxonomy
      • 16.8.4.2.1. By Disease Type
      • 16.8.4.2.2. By Treatment Type
      • 16.8.4.2.3. By Route of Administration
      • 16.8.4.2.4. By Distribution Channel

17. East Asia Mycobacterium Tuberculosis Treatment Market Analysis 2019-2023 and Forecast 2024-2032

• 17.1. Introduction
• 17.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
• 17.3. Current and Future Market Size (US$ Mn) Analysis and Forecast, By Market Taxonomy, 2024-2032
  • 17.3.1. By Country
    • 17.3.1.1. China
    • 17.3.1.2. Japan
    • 17.3.1.3. South Korea
  • 17.3.2. By Disease Type
  • 17.3.3. By Treatment Type
  • 17.3.4. By Route of Administration
  • 17.3.5. By Distribution Channel
• 17.4. Market Attractiveness Analysis
  • 17.4.1. By Country
  • 17.4.2. By Disease Type
  • 17.4.3. By Treatment Type
  • 17.4.4. By Route of Administration
  • 17.4.5. By Distribution Channel
• 17.5. Market Trends
• 17.6. Key Market Participants - Intensity Mapping
• 17.7. Drivers and Restraints - Impact Analysis
• 17.8. Country Level Analysis & Forecast
  • 17.8.1. China Mycobacterium Tuberculosis Treatment Market Analysis
    • 17.8.1.1. Introduction
    • 17.8.1.2. Market Analysis and Forecast by Market Taxonomy
      • 17.8.1.2.1. By Disease Type
      • 17.8.1.2.2. By Treatment Type
      • 17.8.1.2.3. By Route of Administration
      • 17.8.1.2.4. By Distribution Channel
  • 17.8.2. Japan Mycobacterium Tuberculosis Treatment Market Analysis
    • 17.8.2.1. Introduction
    • 17.8.2.2. Market Analysis and Forecast by Market Taxonomy
      • 17.8.2.2.1. By Disease Type
      • 17.8.2.2.2. By Treatment Type
      • 17.8.2.2.3. By Route of Administration
      • 17.8.2.2.4. By Distribution Channel
  • 17.8.3. South Korea Mycobacterium Tuberculosis Treatment Market Analysis
    • 17.8.3.1. Introduction
    • 17.8.3.2. Market Analysis and Forecast by Market Taxonomy
      • 17.8.3.2.1. By Disease Type
      • 17.8.3.2.2. By Treatment Type
      • 17.8.3.2.3. By Route of Administration
      • 17.8.3.2.4. By Distribution Channel

18. Oceania Mycobacterium Tuberculosis Treatment Market Analysis 2019-2023 and Forecast 2024-2032

• 18.1. Introduction
• 18.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
• 18.3. Current and Future Market Size (US$ Mn) Analysis and Forecast, By Market Taxonomy, 2024-2032
  • 18.3.1. By Country
    • 18.3.1.1. Australia
    • 18.3.1.2. New Zealand
  • 18.3.2. By Disease Type
  • 18.3.3. By Treatment Type
  • 18.3.4. By Route of Administration
  • 18.3.5. By Distribution Channel
• 18.4. Market Attractiveness Analysis
  • 18.4.1. By Country
  • 18.4.2. By Disease Type
  • 18.4.3. By Treatment Type
  • 18.4.4. By Route of Administration
  • 18.4.5. By Distribution Channel
• 18.5. Market Trends
• 18.6. Key Market Participants - Intensity Mapping
• 18.7. Drivers and Restraints - Impact Analysis
• 18.8. Country Level Analysis & Forecast
  • 18.8.1. Australia Mycobacterium Tuberculosis Treatment Market Analysis
    • 18.8.1.1. Introduction
    • 18.8.1.2. Market Analysis and Forecast by Market Taxonomy
      • 18.8.1.2.1. By Disease Type
      • 18.8.1.2.2. By Treatment Type
      • 18.8.1.2.3. By Route of Administration
      • 18.8.1.2.4. By Distribution Channel
  • 18.8.2. New Zealand Mycobacterium Tuberculosis Treatment Market Analysis
    • 18.8.2.1. Introduction
    • 18.8.2.2. Market Analysis and Forecast by Market Taxonomy
      • 18.8.2.2.1. By Disease Type
      • 18.8.2.2.2. By Treatment Type
      • 18.8.2.2.3. By Route of Administration
      • 18.8.2.2.4. By Distribution Channel

19. Middle East and Africa (MEA) Mycobacterium Tuberculosis Treatment Market Analysis 2019-2023 and Forecast 2024-2032

• 19.1. Introduction
• 19.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
• 19.3. Current and Future Market Size (US$ Mn) Analysis and Forecast, By Market Taxonomy, 2024-2032
  • 19.3.1. By Country
    • 19.3.1.1. GCC Countries
    • 19.3.1.2. Turkey
    • 19.3.1.3. North Africa
    • 19.3.1.4. South Africa
    • 19.3.1.5. Rest of Middle East and Africa
  • 19.3.2. By Disease Type
  • 19.3.3. By Treatment Type
  • 19.3.4. By Route of Administration
  • 19.3.5. By Distribution Channel
• 19.4. Market Attractiveness Analysis
  • 19.4.1. By Country
  • 19.4.2. By Disease Type
  • 19.4.3. By Treatment Type
  • 19.4.4. By Route of Administration
  • 19.4.5. By Distribution Channel
• 19.5. Market Trends
• 19.6. Key Market Participants - Intensity Mapping
• 19.7. Drivers and Restraints - Impact Analysis
• 19.8. Country Level Analysis & Forecast
  • 19.8.1. GCC Countries Mycobacterium Tuberculosis Treatment Market Analysis
    • 19.8.1.1. Introduction
    • 19.8.1.2. Market Analysis and Forecast by Market Taxonomy
      • 19.8.1.2.1. By Disease Type
      • 19.8.1.2.2. By Treatment Type
      • 19.8.1.2.3. By Route of Administration
      • 19.8.1.2.4. By Distribution Channel
  • 19.8.2. Turkey Mycobacterium Tuberculosis Treatment Market Analysis
    • 19.8.2.1. Introduction
    • 19.8.2.2. Market Analysis and Forecast by Market Taxonomy
      • 19.8.2.2.1. By Disease Type
      • 19.8.2.2.2. By Treatment Type
      • 19.8.2.2.3. By Route of Administration
      • 19.8.2.2.4. By Distribution Channel
  • 19.8.3. North Africa Mycobacterium Tuberculosis Treatment Market Analysis
    • 19.8.3.1. Introduction
    • 19.8.3.2. Market Analysis and Forecast by Market Taxonomy
      • 19.8.3.2.1. By Disease Type
      • 19.8.3.2.2. By Treatment Type
      • 19.8.3.2.3. By Route of Administration
      • 19.8.3.2.4. By Distribution Channel
  • 19.8.4. South Africa Mycobacterium Tuberculosis Treatment Market Analysis
    • 19.8.4.1. Introduction
    • 19.8.4.2. Market Analysis and Forecast by Market Taxonomy
      • 19.8.4.2.1. By Disease Type
      • 19.8.4.2.2. By Treatment Type
      • 19.8.4.2.3. By Route of Administration
      • 19.8.4.2.4. By Distribution Channel

20. Market Structure Analysis

• 20.1. Market Analysis by Tier of Companies
• 20.2. Market Share Analysis of Top Players
• 20.3. Market Presence Analysis
  • 20.3.1. Regional Footprint Analysis
  • 20.3.2. Channel Footprint Analysis

21. Competition Analysis

• 21.1. Competition Dashboard
• 21.2. Competition Benchmarking
• 21.3. Competition Deep Dive
  • 21.3.1. AstraZeneca
    • 21.3.1.1. Overview
    • 21.3.1.2. Product Portfolio
    • 21.3.1.3. Key Financials
    • 21.3.1.4. SWOT Analysis
    • 21.3.1.5. Sales Footprint
    • 21.3.1.6. Strategy Overview
    • 21.3.1.7. Key Developments
      • 21.3.1.7.1. Marketing Strategies
      • 21.3.1.7.2. Channel Strategies
  • 21.3.2. Johnson & Johnson Private Limited
    • 21.3.2.1. Overview
    • 21.3.2.2. Product Portfolio
    • 21.3.2.3. Key Financials
    • 21.3.2.4. SWOT Analysis
    • 21.3.2.5. Sales Footprint
    • 21.3.2.6. Strategy Overview
    • 21.3.2.7. Key Developments
      • 21.3.2.7.1. Marketing Strategies
      • 21.3.2.7.2. Channel Strategies
  • 21.3.3. Eli Lilly and Company
    • 21.3.3.1. Overview
    • 21.3.3.2. Product Portfolio
    • 21.3.3.3. Key Financials
    • 21.3.3.4. SWOT Analysis
    • 21.3.3.5. Sales Footprint
    • 21.3.3.6. Strategy Overview
    • 21.3.3.7. Key Developments
      • 21.3.3.7.1. Marketing Strategies
      • 21.3.3.7.2. Channel Strategies
  • 21.3.4. F. Hoffmann-La Roche Ltd.
    • 21.3.4.1. Overview
    • 21.3.4.2. Product Portfolio
    • 21.3.4.3. Key Financials
    • 21.3.4.4. SWOT Analysis
    • 21.3.4.5. Sales Footprint
    • 21.3.4.6. Strategy Overview
    • 21.3.4.7. Key Developments
      • 21.3.4.7.1. Marketing Strategies
      • 21.3.4.7.2. Channel Strategies
  • 21.3.5. Mylan N.V.
    • 21.3.5.1. Overview
    • 21.3.5.2. Product Portfolio
    • 21.3.5.3. Key Financials
    • 21.3.5.4. SWOT Analysis
    • 21.3.5.5. Sales Footprint
    • 21.3.5.6. Strategy Overview
    • 21.3.5.7. Key Developments
      • 21.3.5.7.1. Marketing Strategies
      • 21.3.5.7.2. Channel Strategies
  • 21.3.6. Teva Pharmaceutical Industries Ltd.
    • 21.3.6.1. Overview
    • 21.3.6.2. Product Portfolio
    • 21.3.6.3. Key Financials
    • 21.3.6.4. SWOT Analysis
    • 21.3.6.5. Sales Footprint
    • 21.3.6.6. Strategy Overview
    • 21.3.6.7. Key Developments
      • 21.3.6.7.1. Marketing Strategies
      • 21.3.6.7.2. Channel Strategies
  • 21.3.7. Sanofi
    • 21.3.7.1. Overview
    • 21.3.7.2. Product Portfolio
    • 21.3.7.3. Key Financials
    • 21.3.7.4. SWOT Analysis
    • 21.3.7.5. Sales Footprint
    • 21.3.7.6. Strategy Overview
    • 21.3.7.7. Key Developments
      • 21.3.7.7.1. Marketing Strategies
      • 21.3.7.7.2. Channel Strategies
  • 21.3.8. Novartis AG
    • 21.3.8.1. Overview
    • 21.3.8.2. Product Portfolio
    • 21.3.8.3. Key Financials
    • 21.3.8.4. SWOT Analysis
    • 21.3.8.5. Sales Footprint
    • 21.3.8.6. Strategy Overview
    • 21.3.8.7. Key Developments
      • 21.3.8.7.1. Marketing Strategies
      • 21.3.8.7.2. Channel Strategies
  • 21.3.9. Sun Pharmaceutical Industries Ltd.
    • 21.3.9.1. Overview
    • 21.3.9.2. Product Portfolio
    • 21.3.9.3. Key Financials
    • 21.3.9.4. SWOT Analysis
    • 21.3.9.5. Sales Footprint
    • 21.3.9.6. Strategy Overview
    • 21.3.9.7. Key Developments
      • 21.3.9.7.1. Marketing Strategies
      • 21.3.9.7.2. Channel Strategies
  • 21.3.10. Aurobindo Pharma
    • 21.3.10.1. Overview
    • 21.3.10.2. Product Portfolio
    • 21.3.10.3. Key Financials
    • 21.3.10.4. SWOT Analysis
    • 21.3.10.5. Sales Footprint
    • 21.3.10.6. Strategy Overview
    • 21.3.10.7. Key Developments
      • 21.3.10.7.1. Marketing Strategies
      • 21.3.10.7.2. Channel Strategies
  • 21.3.11. Lupin
    • 21.3.11.1. Overview
    • 21.3.11.2. Product Portfolio
    • 21.3.11.3. Key Financials
    • 21.3.11.4. SWOT Analysis
    • 21.3.11.5. Sales Footprint
    • 21.3.11.6. Strategy Overview
    • 21.3.11.7. Key Developments
      • 21.3.11.7.1. Marketing Strategies
      • 21.3.11.7.2. Channel Strategies
  • 21.3.12. Allergan
    • 21.3.12.1. Overview
    • 21.3.12.2. Product Portfolio
    • 21.3.12.3. Key Financials
    • 21.3.12.4. SWOT Analysis
    • 21.3.12.5. Sales Footprint
    • 21.3.12.6. Strategy Overview
    • 21.3.12.7. Key Developments
      • 21.3.12.7.1. Marketing Strategies
      • 21.3.12.7.2. Channel Strategies
  • 21.3.13. Merck & Co., Inc.
    • 21.3.13.1. Overview
    • 21.3.13.2. Product Portfolio
    • 21.3.13.3. Key Financials
    • 21.3.13.4. SWOT Analysis
    • 21.3.13.5. Sales Footprint
    • 21.3.13.6. Strategy Overview
    • 21.3.13.7. Key Developments
      • 21.3.13.7.1. Marketing Strategies
      • 21.3.13.7.2. Channel Strategies
  • 21.3.14. Pfizer Inc.
    • 21.3.14.1. Overview
    • 21.3.14.2. Product Portfolio
    • 21.3.14.3. Key Financials
    • 21.3.14.4. SWOT Analysis
    • 21.3.14.5. Sales Footprint
    • 21.3.14.6. Strategy Overview
    • 21.3.14.7. Key Developments
      • 21.3.14.7.1. Marketing Strategies
      • 21.3.14.7.2. Channel Strategies
  • 21.3.15. GlaxoSmithKline plc
    • 21.3.15.1. Overview
    • 21.3.15.2. Product Portfolio
    • 21.3.15.3. Key Financials
    • 21.3.15.4. SWOT Analysis
    • 21.3.15.5. Sales Footprint
    • 21.3.15.6. Strategy Overview
    • 21.3.15.7. Key Developments
      • 21.3.15.7.1. Marketing Strategies
      • 21.3.15.7.2. Channel Strategies
  • 21.3.16. Hikma Pharmaceuticals PLC
    • 21.3.16.1. Overview
    • 21.3.16.2. Product Portfolio
    • 21.3.16.3. Key Financials
    • 21.3.16.4. SWOT Analysis
    • 21.3.16.5. Sales Footprint
    • 21.3.16.6. Strategy Overview
    • 21.3.16.7. Key Developments
      • 21.3.16.7.1. Marketing Strategies
      • 21.3.16.7.2. Channel Strategies
  • 21.3.17. Cipla Inc.
    • 21.3.17.1. Overview
    • 21.3.17.2. Product Portfolio
    • 21.3.17.3. Key Financials
    • 21.3.17.4. SWOT Analysis
    • 21.3.17.5. Sales Footprint
    • 21.3.17.6. Strategy Overview
    • 21.3.17.7. Key Developments
      • 21.3.17.7.1. Marketing Strategies
      • 21.3.17.7.2. Channel Strategies
  • 21.3.18. Endo International plc
    • 21.3.18.1. Overview
    • 21.3.18.2. Product Portfolio
    • 21.3.18.3. Key Financials
    • 21.3.18.4. SWOT Analysis
    • 21.3.18.5. Sales Footprint
    • 21.3.18.6. Strategy Overview
    • 21.3.18.7. Key Developments
      • 21.3.18.7.1. Marketing Strategies
      • 21.3.18.7.2. Channel Strategies
  • 21.3.19. Otsuka Pharmaceutical Co., Ltd.
    • 21.3.19.1. Overview
    • 21.3.19.2. Product Portfolio
    • 21.3.19.3. Key Financials
    • 21.3.19.4. SWOT Analysis
    • 21.3.19.5. Sales Footprint
    • 21.3.19.6. Strategy Overview
    • 21.3.19.7. Key Developments
      • 21.3.19.7.1. Marketing Strategies
      • 21.3.19.7.2. Channel Strategies
  • 21.3.20. STI Pharma, LLC
    • 21.3.20.1. Overview
    • 21.3.20.2. Product Portfolio
    • 21.3.20.3. Key Financials
    • 21.3.20.4. SWOT Analysis
    • 21.3.20.5. Sales Footprint
    • 21.3.20.6. Strategy Overview
    • 21.3.20.7. Key Developments
      • 21.3.20.7.1. Marketing Strategies
      • 21.3.20.7.2. Channel Strategies

22. Assumptions and Acronyms Used

23. Research Methodology